Cognition Therapeutics (CGTX)
(Delayed Data from NSDQ)
$0.44 USD
0.00 (0.02%)
Updated Oct 4, 2024 03:59 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CGTX 0.44 0.00(0.02%)
Will CGTX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CGTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGTX
Is Accelerate Diagnostics (AXDX) Outperforming Other Medical Stocks This Year?
CGTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGTX
Cognition Therapeutics supports Lewy Body Dementia Awareness Month
Cognition Therapeutics Highlights CT1812 Potential in CNS Disorders
12 Health Care Stocks Moving In Monday's After-Market Session
Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences
Cognition Therapeutics Shares Investor Presentation Update